Public health perspectives of preeclampsia in developing countries: implication for health system strengthening

Kayode O Osungbade, Olusimbo K Ige, Kayode O Osungbade, Olusimbo K Ige

Abstract

Objectives: Review of public health perspectives of preeclampsia in developing countries and implications for health system strengthening.

Methods: Literature from Pubmed (MEDLINE), AJOL, Google Scholar, and Cochrane database were reviewed.

Results: The prevalence of preeclampsia in developing countries ranges from 1.8% to 16.7%. Many challenges exist in the prediction, prevention, and management of preeclampsia. Promising prophylactic measures like low-dose aspirin and calcium supplementation need further evidence before recommendation for use in developing countries. Treatment remains prenatal care, timely diagnosis, proper management, and timely delivery. Prevailing household, community, and health system factors limiting effective control of preeclampsia in these countries were identified, and strategies to strengthen health systems were highlighted.

Conclusion: Overcoming the prevailing challenges in the control of preeclampsia in developing countries hinges on the ability of health care systems to identify and manage women at high risk.

References

    1. Medicine for Africa - Medical Information Service. preeclampsia/ eclampsia. 2008,
    1. Shah AK. Preeclampsia and Eclampsia. 2009, .
    1. World Health Organization. Global Program to Conquer Preeclampsia/Eclampsia. 2002.
    1. Dolea C, AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. In: Global Burden of Diseases; 2000; World Health Organization;
    1. Shah A, Fawole B, M’Imunya JM, et al. Cesarean delivery outcomes from the WHO global survey on maternal and perinatal health in Africa. International Journal of Gynecology and Obstetrics. 2009;107(3):191–197.
    1. McClure EM, Saleem S, Pasha O, Goldenberg RL. Stillbirth in developing countries: a review of causes, risk factors and prevention strategies. Journal of Maternal-Fetal and Neonatal Medicine. 2009;22(3):183–190.
    1. Igberase G, Ebeigbe P. Eclampsia: ten-years of experience in a rural tertiary hospital in the Niger delta, Nigeria. Journal of Obstetrics and Gynaecology. 2006;26(5):414–417.
    1. Adamu YM, Salihu HM, Sathiakumar N, Alexander GR. Maternal mortality in Northern Nigeria: a population-based study. European Journal of Obstetrics Gynecology and Reproductive Biology. 2003;109(2):153–159.
    1. Ikechebelu JI, Okoli CC. Review of eclampsia at the Nnamdi Azikiwe University teaching hospital, Nnewi (January 1996-December 2000) Journal of Obstetrics and Gynaecology. 2002;22(3):287–290.
    1. Onuh SO, Aisien AO. Maternal and fetal outcome in eclamptic patients in Benin City, Nigeria. Journal of Obstetrics and Gynaecology. 2004;24(7):765–768.
    1. Onakewhor JUE, Gharoro EP. Changing trends in maternal mortality in a developing country. Nigerian Journal of Clinical Practice. 2008;11(2):111–120.
    1. Duley L. Pre-eclampsia and the hypertensive disorders of pregnancy. British Medical Bulletin. 2003;67:161–176.
    1. WHO. Make every mother and child count, in The world health report 2005. Geneva, Switzerland: World Health Organization; 2005.
    1. WHO. Coverage of Maternity Care: A Listing of Available Information. Geneva, Switzerland: World Health Organization; 2004.
    1. Kimbally KG, Barassoumbi H, Buambo SF, et al. Arterial hypertension: epidemiological aspects and risk factors on pregnant and delivered woman. Dakar Médical. 2007;52(2):148–152.
    1. Mahaba HM, Ismail NA, El Damaty SI, Kamel HA. Pre-eclampsia: epidemiology and outcome of 995 cases. The Journal of the Egyptian Public Health Association. 2001;76(5-6):357–368.
    1. Thiam M, Goumbala M, Gning SB, Fall PD, Cellier C, Perret JL. Maternel and fetal prognosis of hypertension and pregnancy in Africa (Senegal) Journal de Gynecologie Obstetrique et Biologie de la Reproduction. 2003;32(1):35–38.
    1. Teklu S, Gaym A. Prevalence and clinical correlates of the hypertensive disorders of pregnancy at Tikur Anbessa Hospital, Addis Ababa, Ethiopia. Ethiopian Medical Journal. 2006;44(1):17–26.
    1. Omole-Ohonsi A, Ashimi AO. Pre-eclampsia: a study of risk factors. Nigerian Medical Practitioner. 2008;53(6):99–102.
    1. Olopade FE, Lawoyin TO. Maternal mortality in a Nigerian Maternity Hospital. African Journal Biomedical Research. 2008;11(3):267–273.
    1. Population Council Nigeria. Administering Magnesium Sulfate to Treat Severe Pre-eclampsia and Eclampsia. 2009, .
    1. Wagner LK. Diagnosis and management of preeclampsia. American Family Physician. 2004;70(12):2317–2324.
    1. Kharb S. Serum markers in pre-eclampsia. Biomarkers. 2009;14(6):395–400.
    1. Audibert F, Boucoiran I, An N, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. American Journal of Obstetrics and Gynecology. 2010;203(4):383.e1–383.e8.
    1. Yale University. Simple test can help predict and diagnose preeclampsia. ScienceDaily. February 5, 2010
    1. Papageorghiou AT, Campbell S. First trimester screening for preeclampsia. Current Opinion in Obstetrics and Gynecology. 2006;18(6):594–600.
    1. Louden K, Kilby M. Low-dose aspirin: the rationale for preventing pre-eclampsia and intra-uterine growth retardation: a role after CLASP? In: Bonnar J, editor. Recent Advances in Obstetrics and Gynaecology, No 19. Edinburgh, UK: Churchill Livingstone; 1995.
    1. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstetrics and Gynecology. 2010;116(2):402–414.
    1. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. British Medical Journal. 2001;322(7282):329–333.
    1. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database of Systematic Reviews. 2000;(2) Article ID CD000492.
    1. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews. 2002;(1) Article ID CD001059.
    1. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews. 2010;8 Article ID CD001059.
    1. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. Journal of Clinical Endocrinology and Metabolism. 2007;92(9):3517–3522.
    1. Marya RK, Rathee S, Manrow M. Effect of calcium and vitamin D supplementation on toxaemia of pregnancy. Gynecologic and Obstetric Investigation. 1987;24(1):38–42.
    1. Olsen SF, Secher NJ. A possible preventive effect of low-dose fish oil on early delivery and pre-eclampsia: Indications from a 50-year-old controlled trial. British Journal of Nutrition. 1990;64(3):599–609.
    1. Bodnar LM, Tang G, Ness RB, Harger G, Roberts JM. Periconceptional multivitamin use reduces the risk of preeclampsia. American Journal of Epidemiology. 2006;164(5):470–477.
    1. Roberts JM, Balk JL, Bodnar LM, Belizán JM, Bergel E, Martinez A. Nutrient involvement in preeclampsia. Journal of Nutrition. 2003;133(5):1684S–1692S.
    1. Wen SW, Chen XIK, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. American Journal of Obstetrics and Gynecology. 2008;198(1):45.e1–45.e7.
    1. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354(9181):810–816.
    1. Villar J, Purwar M, Merialdi M, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and e among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG. 2009;116(6):780–788.
    1. Akinola O, et al. Improving the clinical outcome in cases of eclampsia: the experience at Lagos State University Teaching Hospital, Ikeja. The Internet Journal of Third World Medicine. 2008;6(2)
    1. Wasim T, Gull M, Siddiq S. Eclampsia, a major cause of maternal & perinatal morbidity and mortality. The Professional. 2004;11(3):1–6.
    1. Brunson J. Confronting maternal mortality, controlling birth in Nepal: the gendered politics of receiving biomedical care at birth. Social Science and Medicine. 2010;71(10):1719–1727.
    1. Begum MR, Begum A, Quadir E, Akhter S, Shamsuddin L. Eclampsia: still a problem in Bangladesh. MedGenMed. 2004;6(4):52–54.
    1. Bracken H. Barriers to magnesium sulfate use for pre-eclampsia: a case study from India. In: Proceedings of the Global Maternal Health Conference; 2010; New Delhi, India.
    1. Richard F, Witter S, De Brouwere V. Innovative approaches to reducing financial barriers to obstetric care in low-income countries. American Journal of Public Health. 2010;100(10):1845–1852.
    1. Olusanya BO, Alakija OP, Inem VA. Non-uptake of facility-based maternity services in an inner-city community in Lagos, Nigeria: an observational study. Journal of Biosocial Science. 2010;42(3):341–358.
    1. NPC. Nigeria Demographic and Health Survey 2008. Abuja, Nigeria: National Population Commission Federal Republic of Nigeria; 2009.
    1. Onah HE, Okaro JM, Umeh U, Chigbu CO. Maternal mortality in health institutions with emergency obstetric care facilities in Enugu State, Nigeria. Journal of Obstetrics and Gynaecology. 2005;25(6):569–574.
    1. Ige OK, Nwachukwu CC. Health care seeking behaviour among market traders in Ibarapa Central Local Government, Nigeria. The Internet Journal of Health. 2009;9(2)
    1. Onwujekwe O, Uzochukwu B. Socio-economic and geographic differentials in costs and payment strategies for primary healthcare services in Southeast Nigeria. Health Policy. 2005;71(3):383–397.
    1. Ige OK, Nwachukwu CC. Areas of dissatisfaction with primary health care services in government owned health facilities in a semi urban community in Nigeria. Journal of Rural and Tropical Public Health. 2010;9:19–23.
    1. Tukur J, Muhammad Z. Management of eclampsia at AKTH: before and after magnesium sulphate. Nigerian Journal of Medicine. 2010;19(1):104–107.
    1. Diaz C. Magnesium sulfate use for the treatment of severe preeclampsia and eclampsia in Mexico. In: Proceedings of the Global Maternal Health Conference; 2010; New Delhi, India.
    1. Getaneh W, Kumbi S. Use of magnesium sulfate in pre-eclampsia and eclampsia in teaching hospitals in Addis Ababa: a practice audit. Ethiopian Medical Journal. 2010;48(2):157–164.
    1. Woelk G, Daniels K, Cliff J, et al. Translating research into policy: lessons learned from eclampsia treatment and malaria control in three southern African countries. Health Research Policy and Systems. 2009;7, article no. 31
    1. Tugwell P, Robinson V, Morris E. Center for Global, International and Regional Studies. Santa Cruz, Calif, USA: University of California; 2007. Mapping global health inequlities: challenges and opportunities.
    1. Aaserud M, Lewin S, Innvaer S, et al. Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia. BMC Health Services Research. 2005;5, article no. 68
    1. WHO. Antenatal Care, in Report of a Technical Working Group. Geneva, Switzerland: World Health Organisation; 1994.
    1. Conde-Agudelo A, Belizán JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. British Journal of Obstetrics and Gynaecology. 2000;107(1):75–83.
    1. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KÅ, Smith GD, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. British Medical Journal. 2007;335(7627):978–981.
    1. Packer CS. Biochemical markers and physiological parameters as indices for identifying patients at risk of developing pre-eclampsia. Journal of Hypertension. 2005;23(1):45–46.
    1. Papageorghiou AT, Yu CKH, Erasmus IE, Cuckle HS, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. BJOG. 2005;112(6):703–709.
    1. WHO. Antenatal Care in Developing Countries: Promises, Achievements and Missed Opportunities. Geneva, Switzerland: World Health Organization; 2003.
    1. Hermida RC, Ayala DE, Iglesias M. Circadian rhythm of blood pressure challenges office values as the “gold standard” in the diagnosis of gestational hypertension. Chronobiology International. 2003;20(1):135–156.
    1. Could oedema and proteinuria in pregnancy be used to screen for high risk?: The WHO International Collaborative Study of Hypertensive Disorders of Pregnancy. Paediatric and Perinatal Epidemiology. 1988;2(1):25–42.
    1. Schroeder BM. ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. American Family Physician. 2002;66(2):330–331.
    1. Duley L. Pre-eclampsia, eclampsia, and hypertension. Clinical Evidence. 2008;2008:p. 1402.
    1. Duley L. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321):1877–1890.
    1. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Systematic Reviews. 2003;(4) Article ID CD000127.
    1. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database of Systematic Reviews. 2003;(4) Article ID CD000128.
    1. Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database of Systematic Reviews. 2000;(3) Article ID CD002960.
    1. Aaserud M, Lewin S, Innvaer S, et al. Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia. BMC Health Services Research. 2005;5, article no. 68
    1. Chigbu B, Onwere S, Kamanu CI, Aluka C, Okoro O, Adibe E. Pregnancy outcome in booked and unbooked mothers in South Eastern Nigeria. East African Medical Journal. 2009;86(6):267–271.
    1. Qiu L, Lin J, Ma Y, et al. Improving the maternal mortality ratio in Zhejiang Province, China, 1988–2008. Midwifery. 2010;26(5):544–548.
    1. Lawn JE, Kinney M, Lee AC, et al. Reducing intrapartum-related deaths and disability: can the health system deliver? International Journal of Gynaecology and Obstetrics. 2009;107:S123–S140.
    1. Lim SS, Dandona L, Hoisington JA, James SL, Hogan MC, Gakidou E. India’s Janani Suraksha Yojana, a conditional cash transfer programme to increase births in health facilities: an impact evaluation. The Lancet. 2010;375(9730):2009–2023.
    1. Prata N, Passano P, Sreenivas A, Gerdts CE. Maternal mortality in developing countries: challenges in scaling-up priority interventions. Women’s Health. 2010;6(2):311–327.
    1. Olsen ØE. The impact of global health initiatives on trust in health care provision under extreme resource scarcity: presenting an agenda for debate from a case study of emergency obstetric care in Northern Tanzania. Health Research Policy and Systems. 2010;8, article no. 14
    1. Ijadunola KT, Ijadunola MY, Esimai OA, Abiona TC. New paradigm old thinking: The case for emergency obstetric care in the prevention of maternal mortality in Nigeria. BMC Women’s Health. 2010;10, article no. 6
    1. Lee AC, Lawn JE, Cousens S, et al. Linking families and facilities for care at birth: what works to avert intrapartum-related deaths? International Journal of Gynaecology and Obstetrics. 2009;107:S65–S86.
    1. Sorensen BL, Elsass P, Nielsen BB, Massawe S, Nyakina J, Rasch V. Substandard emergency obstetric care—a confidential enquiry into maternal deaths at a regional hospital in Tanzania. Tropical Medicine and International Health. 2010;15(8):894–900.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel